Metropolis Healthcare Ltd. · NSE:METROPOLIS
Metropolis Healthcare — Q4 FY26 Earnings Presentation
32 slides from Metropolis Healthcare's earnings presentation, May 13, 2026
Slide 1: Cover letter to stock exchanges: Investor Presentation
Ref: MHL/Sec&Legal/2026-27/10 May 13, 2026 To, BSE Limited National Stock Exchange of India Ltd. Scrip Code: 542650 Scrip Symbol: METROPOLIS Dear Sir/Madam, Sub: Investor Presentation Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclos
Slide 2: Metropolis Healthcare Limited Q4 & FY26 Investor Presentation
METROPOLIS HEALTHCARE LIMITED Q4 & FY26 INVESTOR PRESENTATION
Slide 3: Safe Harbor
Safe Harbor This presentation and the accompanying slides (the “Presentation”), which have been prepared by Metropolis Healthcare Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any
Slide 4: Metropolis – Diagnostics that’s trusted by doctors and patients alike
Metropolis – Diagnostics that’s trusted by doctors and patients alike OUR VISION To be a respected healthcare brand 45+ years of trusted by clinicians, patients and 12% CAGR stakeholders. credible revenue experience Positively impact the lives of patients in growth in last their most anxious times a
Slide 5: Performance & Company Updates – Q4 & FY26
Important Updates & Definitions: Performance & Company Updates – Q4 & FY26 1. MHL Group – Includes acquisitions of Core Diagnostics, DAPIC – Dehradun, Scientific Pathology – Agra and Ambika - Kolhapur 2. MHL Organic – Excludes recent acquisitions of Core Diagnostics, DAPIC – MHL Group MHL Organic 01
Slide 6: Q4 & FY26 Key Financials – MHL Group
Q4 & FY26 Key Financials – MHL Group Q4FY26 • Overall performance driven by robust & sustainable demand coupled with Revenue EBITDA PAT efficiency gains, leading to enhanced profitability INR 425 Cr • Integration of acquired entities - INR 108 Cr INR 51 Cr DAPIC – Dehradun, Scientific +23% YoY +71%
Slide 7: Q4 & FY26 Key Financials – MHL Organic
Q4 & FY26 Key Financials – MHL Organic Q4FY26 • FY26 stands out as a year of compounding, characterized by Revenue EBITDA PAT sustained revenue momentum and meaningful margin expansion. INR 392 Cr INR 107 Cr INR 55 Cr • Revenue growth on the back of strong +15% YoY patient volume growth of 9.3% YoY
Slide 8: Q4 & FY26 Key Performance Indicators – MHL Organic
Q4 & FY26 Key Performance Indicators MHL Organic Excludes recent acquisitions of Core Diagnostics, DAPIC – Dehradun, Scientific Pathology – Agra & Ambika - Kolhapur 6
Slide 9: Q4FY26 Key Performance Indicators
Q4FY26 Key Performance Indicators Patient Volume B2C Revenue B2B Revenue 3.4 Mn • Delivered resilient high single -digit INR 240 Cr INR 152 Cr patient and test volume growth +9% YoY +15% YoY +15% YoY across channels on the back of addition of ~1000 service network added in last 2 years and productiv
Slide 10: FY26 Key Performance Indicators
FY26 Key Performance Indicators Patient Volume B2C Revenue B2B Revenue • B2B growth remained healthy, supported by service quality and 13.5 Mn INR 910 Cr INR 600 Cr stronger client relationships and good quality B2B business built up +7.5% YoY +14% YoY +13% YoY from Corporates and Hospitals • B2C gr
Slide 11: Consistently Delivering Patient & Test Volume Growth
Consistently Delivering Patient & Test Volume Growth Patient Volume (in Mn) Test Volume (in Mn) Q4FY26 Segment Contribution 7.5% 9.7% 8% 9% 12.61 13.53 8% 9% 20% 17% Routine 28.43 26.38 Semi-Special 26% Specialty 3.14 3.43 37% TruHealth 6.62 7.21 Q4FY25 Q4FY26 FY25 FY26 Q4FY25 Q4FY26 FY25 FY26 Reven
Slide 12: B2C revenue growth @ 14% YoY, B2B revenue growing by 13% YoY in FY26
B2C revenue growth @ 14% YoY, B2B revenue growing by 13% YoY in FY26 Contribution TruHealth Growth Specialty Growth • B2C growth was delivered without any new lab additions during FY26, led by productivity gains and better utilization of the existing network B2C • ~500 new centres improved reach, an
Slide 13: TruHealth Revenue grew @ 21% YoY for FY26
TruHealth Revenue grew @ 21% YoY for FY26 o Strong Revenue Momentum, Premium Mix & Digital Acceleration Growth o TruHealth contribution @ 19%, driven by premiumization, AI-powered recommendations and stronger bundle adoption o Premium TruHealth mix rose to 37%, led by vitals, 21% consult and ECG bun
Slide 14: Speciality Revenue grew @ 16% YoY for FY26
Speciality Revenue grew @ 16% YoY for FY26 o Clinician Trust, Scientific Expansion and New Test Launches Driving Growth Specialty Growth o Core Diagnostics capabilities are being scaled across Metropolis’ nationwide B2C and B2B network strengthening specialty cross-sell 16% o Expanded differentiated
Slide 15: Q4 & FY26 Key Performance Indicators – MHL Group
Q4 & FY26 Key Performance Indicators MHL Group Includes recent acquisitions of Core Diagnostics, DAPIC - Dehradun, Scientific Pathology – Agra and Ambika - Kolhapur 13
Slide 16: Q4FY26 Key Performance Indicators
Q4FY26 Key Performance Indicators Q4FY26 Segment Contribution B2C Revenue Patient Volume RPP 17% 19% Routine Semi-Special INR 251 Cr 3.5 Mn INR 1,210 Specialty 26% +20% YoY +11% YoY +11% YoY TruHealth 38% Q4FY26 Segment Revenue Growth Routine 13% B2B Revenue Test Volume RPT Semi-Special 18% INR 174
Slide 17: FY26 Key Performance Indicators
FY26 Key Performance Indicators FY26 Segment Contribution B2C Revenue Patient Volume RPP 18% 17% Routine Semi-Special INR 949 Cr 14.1 Mn INR 1,162 Specialty 26% +19% YoY +12% YoY +10% YoY TruHealth 39% FY26 Segment Revenue Growth Routine 11% B2B Revenue Test Volume RPT Semi-Special 19% INR 697 Cr 29
Slide 18: Diversified Revenue contribution across geographies
Diversified Revenue contribution across geographies Contribution from North India has increased to 17% Revenue Contribution Revenue Contribution (MHL Categorisation) By Region West 30% 28% South 50% Q4FY26 55% Q4FY25 North 5% 6% East 9% 17% Revenue Contribution Revenue Contribution (MHL Categorisati
Slide 19: Building a scalable efficient network
Building a scalable efficient network Laboratory Network Service Network +87 +2,471 5,026 210 212 4,536 199 4,150 175 3,675 161 3,134 119 124 125 2,731 2,555 2,336 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26 Over Last 5 Years ~750 towns 87 Labs Network added 490 C
Slide 20: Q4FY26 Profit & Loss Statement
Q4FY26 Profit & Loss Statement Q4FY26 Q4FY25 (MHL Q4FY26 Profit & Loss Statement (Rs. Crs.) Y-o-Y (MHL Y-o-Y Organic) (MHL Organic) Group) Revenue from Operations 341.7 392.1 14.7% 424.7 23.0% Total Cost 257.8 285.4 316.7 Adj. EBITDA 84.0 106.6 26.9% 108.0 28.5% One-Time Expenses 21.0* 0.0 0.0 Repor
Slide 21: FY26 Profit & Loss Statement
FY26 Profit & Loss Statement FY26 FY25 FY26 Profit & Loss Statement (Rs. Crs.) Y-o-Y (MHL Y-o-Y (MHL Organic) (MHL Organic) Group) Revenue from Operations 1,327.6 1,509.6 13.7% 1,645.8 23.6% Total Cost 1,002.3 1,118.0 1,245.0 Adj. EBITDA 325.3 391.6 20.4% 400.8 23.2% One-Time Expenses 21.0* 0.0 0.0
Slide 22: Balance Sheet Overview – MHL Group
Balance Sheet Overview – MHL Group Equity & Liabilities (Rs. Crs.) Mar-26 Mar-25 Assets (Rs. Crs.) Mar-26 Mar-25 Equity 1524.6 1334.6 Non-current assets 1669.4 1521.4 Equity Share capital 41.5 10.4 Property, Plant and Equipment 215.3 190.3 Other equity 1471.7 1320.6 ROU Assets 194.7 170.3 Non Contro
Slide 23: Metropolis 3.0
Metropolis 3.0 METROP®OLIS
Slide 24: Key Pillars of Metropolis 3.0 Strategy – poised to grow further
Key Pillars of Metropolis 3.0 Strategy – poised to grow further 1 2 Strengthening the Core Expand to Adjacencies Expand market share in core and new while Forging New Alliances geographies with focus on specialized Expand into adjacencies such as and wellness testing, strengthening Top complementary
Slide 25: Driving business growth through Digital Transformation
Driving business growth through Digital Transformation Metropolis is a unique Healthcare Company equipped with CDP, Marketing Cloud, Service Cloud, Sales Cloud, Partner Portal Accurate Efficient 360-Degree Opportunity Case Relationship Reporting & Cross Channel Enhanced Efficient Billing & Patient P
Slide 26: Scientifically driven with strong focus on quality, research and academics
Scientifically driven with strong focus on quality, research and academics Scientific Expansion in Test Menu • New test launched across Oncology, Nephrology, Gynecology and Infectious and Chronic disease segment 314+ New Tests added in FY26 • Focus on NGS/molecular genomics segment growing driven by
Slide 27: Metropolis ESG Goals
Metropolis ESG Goals • Carbon Neutrality by 2043 Emission Goals for a Greener • 45% reduction in emissions intensity by Well identified ESG Focus Areas and Tomorrow 2030 e assessments created as per the materiality matrix based on the GRI, SASB and SDG Frameworks. • Zero waste in offices by 2030 Ach
Slide 28: Key ESG Plans
Key ESG Plans Emissions & Water & Waste Employee Risk Patient Privacy Energy Management Recruitment, Management and Electronic Development and Health Records • Achieve 5% reduction in Retention • Achieve 10% reduction in water usage through • Annual assessments of • Continue to strengthen Career 2.0
Slide 29: CSR at Metropolis – Creating a Positive Impact
CSR at Metropolis – Creating a Positive Impact ADOLESCENT REPRODUCTIVE & SEXUAL HEALTH PREVENTIVE HEALTHCARE MEDENGAGE EMPLOYEE VOLUNTEERING • Empowering Adolescents • Driving Preventive Healthcare • Advancing Healthcare Education & • Fostering Employee-Led Social Through Community-Led Outcomes Acro
Slide 30: ‘Promoter led – Professionally driven’ organisation
‘Promoter led – Professionally driven’ organisation Dr. Sushil Shah Ameera Shah Surendran Chemmenkotil Founder & Non – Executive Promoter & Executive Chairperson Managing Director Non - Independent Director Dynamic Leadership Team for Next Level of Growth Sameer Patel Avadhut Joshi Diya Suri Dr. Kir
Slide 31: Recent Awards and Accolades
Recent Awards and Accolades Surendran Chemmenkotil - Top Transformative Healthcare Leaders of April’26 Maharashtra - by Digital Health News Mar’26 Ameera Shah - Top 25 Women Leaders in Healthcare IT - by Digital Health News Mar’26 Ameera Shah -100 Most Influential Women 2026 – by BW Businessworld Am
Slide 32: For further information, please contact
For further information, please contact: Company : Investor Relations Advisors : http://www.sgapl.net/images/sgapl_logo.jpg Metropolis Healthcare Ltd. Strategic Growth Advisors Pvt. Ltd. CIN – L73100MH2000PLC192798 CIN - U74140MH2010PTC204285 Mr. Kamlesh Kulkarni Mr. Shogun Jain / Mr. Sagar Shroff E
Metropolis Healthcare — Q4 FY26 Earnings Presentation on 6ix